Accordingly and in line with the results from Apte et al., the blockade of IL-17 in mouse cancer models results in a reduction of lung tumor metastasis and the genetic ablation of IL-17C in a KrasG12D lung cancer mouse model improved the response to anti-PD1 treatment (Ritzmann et al., 2019), (Chang et al., 2014; Salazar et al., 2020; Figure 2A). This evidence concerns the gene IL17A and lung carcinoma.